Telo Genomics Valuation
| TELO Stock | CAD 0.12 0.01 9.09% |
Telo Genomics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Telo Genomics Corp from inspecting the company fundamentals such as Shares Outstanding of 74.56 M, price to book of 220.96 X, and Return On Equity of -1.69 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Telo Genomics' valuation include:
Price Book 220.96 | Enterprise Value 6.9 M | Enterprise Value Ebitda (6.32) |
Overvalued
Today
Please note that Telo Genomics' price fluctuation is out of control at this time. Calculation of the real value of Telo Genomics Corp is based on 3 months time horizon. Increasing Telo Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Telo stock is determined by what a typical buyer is willing to pay for full or partial control of Telo Genomics Corp. Since Telo Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telo Stock. However, Telo Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.12 | Real 0.11 | Hype 0.12 |
The intrinsic value of Telo Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telo Genomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telo Genomics Corp helps investors to forecast how Telo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telo Genomics more accurately as focusing exclusively on Telo Genomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Telo Genomics' intrinsic value based on its ongoing forecasts of Telo Genomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Telo Genomics' closest peers.
Telo Genomics Cash |
|
Telo Valuation Trend
Analysing the historical paterns of Telo Genomics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Telo Genomics Corp over time and is usually enough for investors to make rational market timing decisions.
Telo Genomics Total Value Analysis
Telo Genomics Corp is at this time expected to have takeover price of 6.94 M with market capitalization of 8.57 M, debt of 32.5 K, and cash on hands of 24.25 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Telo Genomics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.94 M | 8.57 M | 32.5 K | 24.25 K |
Telo Genomics Asset Utilization
One of the ways to look at asset utilization of Telo is to check how much profit was generated for every dollar of assets it reports. Telo Genomics Corp has a negative utilization of assets of -0.87 %, losing C$0.008732 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Telo Genomics Corp shows how discouraging it operates for each dollar spent on its assets.Telo Genomics Ownership Allocation
Telo Genomics Corp shows a total of 74.56 Million outstanding shares. Telo Genomics Corp has 5.34 % of its outstanding shares held by insiders and 2.74 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Telo Genomics Profitability Analysis
Net Loss for the year was (2.82 M) with profit before overhead, payroll, taxes, and interest of 0.About Telo Genomics Valuation
Our relative valuation model uses a comparative analysis of Telo Genomics. We calculate exposure to Telo Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telo Genomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -29.8 K | -31.3 K |
Additional Tools for Telo Stock Analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.